A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer von EHLEN, T.G., HOSKINS, P.J., MILLER, D., WHITESIDE, T.L., NICODEMUS, C.F., SCHULTES, B.C., SWENERTON, K.D.

Volltext

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity von de Bono, J. S., Rha, S. Y., Stephenson, J., Schultes, B. C., Monroe, P., Eckhardt, G. S., Hammond, L. A., Whiteside, T. L., Nicodemus, C. F., Cermak, J. M., Rowinsky, E. K., Tolcher, A. W.

Volltext

A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer von Ehlen, T.G., Hoskins, P.J., Miller, D., Whiteside, T.L., Nicodemus, C.F., Schultes, B.C., Swenerton, K.D.

Volltext

The human serglycin gene. Nucleotide sequence and methylation pattern in human promyelocytic leukemia HL-60 cells and T-lymphoblast Molt-4 cells von HUMPHRIES, D. E, NICODEMUS, C. F, SCHILLER, V, STEVENS, R. L

Volltext

In vivo Leukocytes Labeling Using a Platelet Factor 4–Derived Heparin Binding Peptide Technetium Complex von Nicodemus, C.F., Moyer, B.R., Lister-James, J.

Volltext

815 Intravenous administration of a potential T cell toleragenic peptide to cat sensitive patients von Norman, P.S., Pasatiempo, A.M.G., Creticos, P.S., Nicodemus, C.F., Jones, N.H., Lichtenstein, L.M., Gefter, M.L.

Volltext